Healx raised $47 million in a Series C funding round led by R42 Group and Atomico to develop treatments for rare diseases including neurofibromatosis Type 1.
Balderton CapitalVU Venture PartnersO2hAyana CapitalBtovGlobal BrainJonathan MilnerAtomicoR42 Group
Description
Healx has announced the completion of a $47 million Series C financing to support its pipeline of medicines. The funding will advance the lead program HLX-1502 through a Phase 2 clinical trial for neurofibromatosis Type 1.
Who to call at Healx, and when
A new round usually means Healx is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Healx raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Healx, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Healx. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Healx
Location
Cambridge, England, United Kingdom
About
Healx is an AI-enabled, clinical-stage biotech company specializing in rare diseases. Co-founded by its chairman David Brown and Tim Guilliams, its mission is to apply emerging technologies to accelerate the discovery of treatments for rare diseases. The company's pipeline includes innovative therapies targeting conditions such as neurofibromatosis Type 1, utilizing their proprietary Healnet discovery platform. Healx is committed to harnessing AI to identify and develop new therapeutic opportunities for patients with significant unmet medical needs.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Healx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeOtherBiotechnologyHealth CareArtificial IntelligenceTherapeutics